#Paraganglioma Treatment trends
Text
Paraganglioma Treatment Market is Booming Market to Grow at Healthy CAGR forecast by 2026
The Paraganglioma Treatment Market research report is a stunning aide for an imperative thought, improved fundamental authority and better business frameworks. The report joins estimations of the ongoing state of the market, CAGR values, market size and overall industry share, income age and significant changes required later on items. The Paraganglioma Treatment Market report has information and data as graphs, tables and outlines that can be adequately understood by the associations. The market thinks about, bits of learning and investigation joined into this overall Paraganglioma Treatment Market report keeps business focus indisputably into the concentration with which you can reach to the business objectives.
Market Analysis:
Global Paraganglioma Treatment Market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Presence of refined healthcare infrastructure and increase in special designation from the regulatory authorities are the key factors that drive the market
Influencing players of this market are:
Few of the major competitors currently working in the global paraganglioma treatment market are Progenics Pharmaceuticals, Inc, AstraZeneca, Advanced Accelerator Applications, Jubilant Life Sciences Ltd, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Cipla Inc, Amneal Pharmaceuticals LLC, Amerigen Pharmaceuticals Limited, Jiangsu Hengrui Medicine Co., Ltd, Fresenius Kabi AG, ONO PHARMACEUTICAL CO., LTD and others.
Get Exclusive Sample Copy of this Report@
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-paraganglioma-treatment-market
This Paraganglioma Treatment Market report consolidates comprehensive industry examination with exact data and conjectures that offers total research arrangements and brings the most extreme industry clarity for decision making.
Analysis based on various segments-:
This analysis gives an examination of various segments that are relied upon to witness the quickest development amid the estimated forecast frame.
And this is done on the basis of-:
By Type
Sympathetic Paragangliomas
Parasympathetic Paragangliomas
By Site of Origin
Caroid Paragangliomas
Cervical Paragangliomas
Vagal Paragangliomas
Others
By Therapy Type
Radiation Therapy
Chemotherapy
Peptide Receptor Radionuclide Therapy (PRRT)
Others
By Treatment
Medication
Surgery
By Drugs
Iobenguane I 131
Cyclophosphamide
Vincristine
Dacarbazine
Others
By Route of Administration
Oral
Injectable
By End Users
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
By Geography
North America
South America
Europe
Asia-Pacific
Middle East & Africa
S.
Canada
Mexico
Brazil
Rest of South America
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Japan
China
South Korea
India
Australia
Singapore
Thailand
Malaysia
Indonesia
Philippines
Rest of Asia Pacific
South Africa
Rest of Middle East & Africa
Regional Insights-
Regional analysis helps the market players to take an exhaustive assessment of the Paraganglioma Treatment Market region wise so that it becomes easy for them to distinguish and investigate the developing pattern and hidden opportunities all over the world.
The Paraganglioma Treatment Market covers regions such as- South America, North America, Europe, Asia-Pacific, Middle East, and Africa.
Get Detailed TOC@
https://www.databridgemarketresearch.com/toc/?dbmr=global-paraganglioma-treatment-market
Analysis based on Competition-:
The Paraganglioma Treatment Market report presents profiles of key market players and information about different techniques they have utilized, for example, new product dispatches, extensions, understandings, joint endeavors, associations, acquisitions, and others to expand their impressions in this market so as to continue in long run.
Key queries addressed in this report-:
What will be the market size and market share in the upcoming future?
What are the new and hidden opportunities in the market?
Who are the top players in market?
How the challenge goes later on?
Which are the main regions impacting the market growth?
What are the difficulties in future?
Key Issues addressed here-:
Uncertainty of upcoming revenue pockets and growth areas.
Understanding business sector sentiments.
Understanding the most dependable venture focuses.
Competitiveness of Top industry players
Trending factors which are impacting the market growth.
Challenges and threats faced by the leading players
Research strategies and tools used-:
This Paraganglioma Treatment Market research report helps the readers to know about the overall market scenario, strategy to further decide on this market project. It utilizes SWOT analysis, Porter’s Five Forces Analysis and PEST analysis.
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: [email protected]
Report Related :
paresthesia market
pharmaceutical equipment testing market
plexopathy treatment market
#Paraganglioma Treatment#Paraganglioma Treatment share#Paraganglioma Treatment size#Paraganglioma Treatment trends#Paraganglioma Treatment anlysis#Paraganglioma Treatment overview#Paraganglioma Treatment type#Paraganglioma Treatment report#Paraganglioma Treatment research#Paraganglioma Treatment market#Paraganglioma Treatment insight#Paraganglioma Treatment application#.
0 notes
Text
Radiopharmaceutical Theranostics Market to Witness Widespread Expansion by 2031
Radiopharmaceutical Theranostics Market: Introduction
According to the report, the global radiopharmaceutical theranostics market was valued at US$ 0.84 Bn in 2020 and is projected to expand at a CAGR of 11% from 2021 to 2031. Nuclear medicine imaging is primarily based on the principle of using radioactive isotopes attached to specific molecules (i.e., radiopharmaceutical agents or radiotracers) to examine key biologic processes, including disease pathophysiology. Radiopharmaceuticals are agents used for both diagnostic and therapeutic purposes. Organizations across the world classify these differently. According to the WHO, these are categorized into ready-for-use radioactive goods, radionuclide generators, non-radioactive components (“kits”) for the production of labelled compounds containing a radioactive component, and precursors used for radiolabelling other substances prior to administration.
The radiopharmaceutical market is projected to be driven by factors such as increase in therapeutic applications, public awareness, usage of hybrid imaging, technological advancements, efficient diagnosis & treatments, emergence of new radioisotopes, and replacement of traditional equipment.
Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82604
Rise in Prevalence of Cancer to Drive Global Market
The significance of customized medicine has been growing rapidly, owing to a more urgent need to avoid unnecessary and expensive treatments. In radiopharmaceuticals, the theranostics approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets could help predict if a patient would benefit from a particular treatment. According to the International Agency for Research on Cancer, the global cancer burden surged to 19.3 million cases and 10 million cancer deaths in 2020. By 2040, the number of new cancer cases per year is anticipated to reach 29.5 million, with 16.4 million cancer-related deaths.
Radiopharmaceutical theranostics is becoming an increasingly essential component of cancer treatment. Radioiodine is the classic radiotheranostic agent for clinical treatment of thyroid tumors. Radiolabeled metaiodobenzylguanidine is another prominent radiotheranostic drug, which has been used for diagnostic imaging and therapy of neuroblastoma, paraganglioma, and pheochromocytoma patients.
Significant and promising advancements have been made in radiotheranostics for neuroendocrine tumors, prostate cancer, and other conditions. Few instance of radiopharmaceutical theranostics pair are 177Lu/68Ga, 111In, 223Ra/99Tc, 18NaF, 131I/123I, 124I, etc.
Radiopharmaceutical theranostics is gaining traction and will most likely be able to expand its scope to include new cancer biomarkers and indications in future. Hence, rise in the prevalence of cancer is projected to propel the demand for radiopharmaceutical theranostics over the next few years.
Request for Analysis of COVID19 Impact on Radiopharmaceutical Theranostics Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82604
Lutetium (Lu) 177 to Dominate Global Market
In terms of radioisotope, the global radiopharmaceutical theranostics market has been classified into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market in 2020 and the trend is anticipated to continue during the forecast period. The favorable nuclear characteristics as well as easy availability of high activity levels of high specific activity 177Lu are the major factors for the widespread interest in the clinical use of this radionuclide.
Oncology to Offer Lucrative Opportunities
Based on application, the global radiopharmaceutical theranostics market has been categorized into oncology, cardiology, and others. The oncology segment dominated the global radiopharmaceutical theranostics market in 2020. Most of the radioisotopes are used in oncology for diagnosis or radiation therapy. 68 Ga DOTATE and 177 Lu DOTATOC is the commonly used theranostics pair in diagnosis and treatment of neuroendocrine tumors.
High Number of Cyclotrons Facilities to Drive Global Market
In terms of source, the global radiopharmaceutical theranostics market has been bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment dominated the market in 2020. The segment is expected to expand at the highest CAGR from 2021 to 2031. The segment is likely to witness rapid growth, owing to a large number of existing cyclotron facilities across the world.
Request a Sample of Radiopharmaceutical Theranostics Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82604
Targeted Therapeutic (Rx) to be Promising Segment
Based on approach, the global radiopharmaceutical theranostics market has been classified into targeted therapeutic (Rx) and companion diagnostic (DX). The targeted therapeutic (Rx) segment dominated the market in 2020. The segment is projected to expand at the highest CAGR from 2021 to 2031. Increasing evidence supports the efficacy and safety of targeted therapeutics, as well as an increase in overall survival.
Hospitals to be Major End Users
In terms of end user, the global radiopharmaceutical theranostics market has been divided into academic & research institutes, hospitals, and others. The hospitals segment dominated the market in 2020. The segment is anticipated to expand at the highest CAGR from 2021 to 2031. Rise in number of hospital facilities and favorable outcomes of treatment in hospitals due to the availability of a range of treatment options lead to high preference to hospitals.
North America to Lead Radiopharmaceutical Theranostics Market
The global radiopharmaceutical theranostics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2020, followed by Europe. North America accounted for a major share of the global radiopharmaceutical theranostics market in 2020. The high prevalence of neuroendocrine tumors (NETs) drives the radiopharmaceutical theranostics market in North America. Over 12,000 people in the U.S. are diagnosed with neuroendocrine tumors each year. The sensitivity and specificity of Ga-68 and Lu-177 as a theranostics pair have been evaluated in a number of clinical trials. This factor is expected to fuel the growth of the market in the region.
Enquiry before Buying Radiopharmaceutical Theranostics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=82604
Competition Landscape
The global radiopharmaceutical theranostics market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, GE Healthcare, Theragnostics Ltd, NuView Life Sciences, Jubilant Pharma Limited, Lantheus Holdings, Inc., Curium Pharma, Bayer AG, and Clarity Pharmaceuticals. New product development through robust R&D activities and mergers & acquisitions are the key strategies adopted by these players to expand business in the global radiopharmaceutical theranostics market.
More Trending Reports by Transparency Market Research:
https://www.prnewswire.co.uk/news-releases/continuous-r-amp-d-to-expand-therapeutic-use-of-platelet-rich-plasma-prp-in-regenerative-therapies-offer-profitable-opportunities-to-platelet-rich-plasma-market-players-global-market-valuation-to-reach-us-811-34-mn-by-2030-tmr-study-825481498.html
https://www.prnewswire.com/news-releases/increase-in-demand-for-new-therapies-for-effective-management-to-drive-global-menopausal-hot-flashes-treatment-market-says-tmr-301378552.html
https://www.prnewswire.com/news-releases/plant-based-vaccines-market-is-expected-to-reach-us-2-34-billion-by-2031-end-emergence-of-numerous-infectious-diseases-to-fuel-growth-of-the-market-says-tmr-301385503.html
About Us Section:
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!
Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
0 notes
Link
Paraganglioma is also known as pheochromocytoma is ultra-rare neuroendocrine cancers that arise from cells called paraganglia. Paraganglia cells are found near nerve cell bunches called ganglia. Most paraganglioma originate in one of the two adrenal glands located above the kidneys in the back of the upper abdomen.
0 notes
Link
Global Paraganglioma Treatment Market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Presence of refined healthcare infrastructure and increase in special designation from the regulatory authorities are the key factors that drive the market
0 notes
Text
Iodine Market Regional Outlook, Size, Share, Growth, Trends, Demand, Industry Analysis, and Key Player profile by 2023
Market Research Future has published a Cooked Research Report on the Global Iodine Market Research Report- Forecast to 2023
Iodine is a substrate extensively used in a range of applications, such as LCD polarizers, biocides, X-ray contrast media, animal nutrition, health nutrition, fluorochemicals, and pharmaceuticals, among others. As a result, Iodine invariably witnesses massive consumption & demand, garnering huge market prominence. Also, the Global Iodine Market has been growing dramatically over the past couple of years, addressing the augmented demand from the radiologists and others.
According to a leading research firm - Market Research Future (MRFR), the Global Iodine Market is expected to create a significantly large revenue pocket by 2023. In its recently published study, MRFR also asserts that the market would register a CAGR over 4.89% throughout the forecast period (2018 – 2023). Technological advancements in medical imaging technology & techniques and the burgeoning healthcare sector are some of the key driving forces pushing upmarket growth.
Besides, factors such as the increasing numbers of public as well as private diagnostic centers with improved diagnostic imaging services are fostering the market demand. Moreover, the rapidly growing contrast media market propel the market growth to an extent. Adversely, factors such as the high toxicity levels associated with Iodine might pose challenges to market growth.
Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/6424
Nevertheless, the rise in the Iodine deficiency among people, especially the demographics of developing regions would support the growth of the market, creating a huge demand for health supplements.
Global Iodine Market – Competitive Landscape
Fiercely competitive, the Iodine Market appears to be fragmented due to the presence of numerous matured & small-scale players. To gain a considerably large share in the market, players initiate strategies such as mergers & acquisitions, expansion, collaboration, and product & technology launch. They invest heavily in R&D to develop a manufacturing technique that is entirely on a different level compared to their competition.
Industry, Innovation & Related News
February 11, 2019 --- Progenics Pharmaceuticals, Inc. (the US), an oncology company involved in the development of innovative medicines and imaging analysis technology used in the cancer treatments, announced the acquisition of a New Jersey-based manufacturing facility for AZEDRA® for cash consideration of USD 8 MN. The Company has also secured the long-term supply of Iodine necessary to produce both AZEDRA and 1095.
These strategic transactions extend Progenics’ leadership position in radiopharmaceuticals, establishing the infrastructure and manufacturing capabilities to label multiple types of isotopes, including iodine-131. With the acquisition, Progenics is building the capabilities to ensure the supply of AZEDRA.
AZEDRA is the first and only FDA approved radiopharmaceutical available for the treatment of ultra-rare cancers such as pheochromocytoma and paraganglioma. The site serves as the launch facility for AZEDRA and will also provide manufacturing support for the Company’s development stage radiopharmaceuticals, including 1095.
Major Players:
Key Players Leading the Global Iodine Market include Cosayach (Chile), Iofina (US), Deepwater Chemicals (US), Glide Chem Pvt. Ltd. (India), Calibre Chemicals Pvt. Ltd. (India), Itochu Chemical Frontier Corporation (Japan), Independent Iodine (Belgium), ISE Chemical Corporation (Japan), Zen Chemicals (India), JSC Isotope (Russia), Iochem Chemicals Corporation (US), ISR Holding (Azerbaijan), Eskay Iodine Private Limited (India), and GODO Shigen Co. Ltd. (Japan), among others.
Global Iodine Market – Segments
The report is segmented into three market dynamics to widen the scope of understanding,
By Type: Natural Brines and Nitrite Ores, among others.
By Application: LCD Polarizers, Biocides, X-ray Contrast Media, Animal Nutrition, Health Nutrition, Fluorochemicals, Pharmaceuticals, and Catalysts, among others.
By Regions: Europe, North America, Asia Pacific, and the Rest-of-the-World.
Global Iodine Market – Geographical Analysis
Europe is the largest region in the Global Iodine Market. The presence of a proliferating pharmaceutical industry and many industry leaders & market players drive the regional market growth. Heading with the resurging economy in the region, the Iodine Market in Europe would reach a valuation of USD 335.4 MN by 2023. Additionally, increasing healthcare expenditures alongside, the adoption of advanced technologies fosters the growth of the regional market.
The Iodine Market in the North American region accounts for the second-largest market, globally. Rapid growth in medical technologies and drug manufacturing units support the growth of the regional market. Besides, the presence of key pharma companies is boosting market demand. Moreover, increasing emphasis of Iodine manufacturers players in delivering cost-competitive and reliable product supply, foster the growth of the regional market. Heading with the same growth trends, the region is estimated to reach USD 214.1 MN by the end of 2023.
The Asia Pacific Iodine Market is lucrative, too, which is growing significantly. Rapidly increasing healthcare and pharmaceutical sector and the developing economy in the region is supporting the regional market growth. Developing markets in Japan, China, and India are further pushing up the increase in the regional market. Moreover, the rising population and spreading awareness towards the functionalities of contrast media drive the Iodine Market in the region.
Have Any Query? Ask Our Expert @ https://www.marketresearchfuture.com/enquiry/6424
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact:
Market Research Future
+1 646 845 9312
Email: [email protected]
0 notes
Text
Radiopharmaceutical Theranostics Market Key Players, Industry Overview and Forecast Analysis
Radiopharmaceutical Theranostics Market: Introduction
According to the report, the global radiopharmaceutical theranostics market was valued at US$ 0.84 Bn in 2020 and is projected to expand at a CAGR of 11% from 2021 to 2031. Nuclear medicine imaging is primarily based on the principle of using radioactive isotopes attached to specific molecules (i.e., radiopharmaceutical agents or radiotracers) to examine key biologic processes, including disease pathophysiology. Radiopharmaceuticals are agents used for both diagnostic and therapeutic purposes. Organizations across the world classify these differently. According to the WHO, these are categorized into ready-for-use radioactive goods, radionuclide generators, non-radioactive components (“kits”) for the production of labelled compounds containing a radioactive component, and precursors used for radiolabelling other substances prior to administration.
The radiopharmaceutical market is projected to be driven by factors such as increase in therapeutic applications, public awareness, usage of hybrid imaging, technological advancements, efficient diagnosis & treatments, emergence of new radioisotopes, and replacement of traditional equipment.
Request a PDF Brochure- https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82604
Rise in Prevalence of Cancer to Drive Global Market
The significance of customized medicine has been growing rapidly, owing to a more urgent need to avoid unnecessary and expensive treatments. In radiopharmaceuticals, the theranostics approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets could help predict if a patient would benefit from a particular treatment. According to the International Agency for Research on Cancer, the global cancer burden surged to 19.3 million cases and 10 million cancer deaths in 2020. By 2040, the number of new cancer cases per year is anticipated to reach 29.5 million, with 16.4 million cancer-related deaths.
Radiopharmaceutical theranostics is becoming an increasingly essential component of cancer treatment. Radioiodine is the classic radiotheranostic agent for clinical treatment of thyroid tumors. Radiolabeled metaiodobenzylguanidine is another prominent radiotheranostic drug, which has been used for diagnostic imaging and therapy of neuroblastoma, paraganglioma, and pheochromocytoma patients.
Significant and promising advancements have been made in radiotheranostics for neuroendocrine tumors, prostate cancer, and other conditions. Few instance of radiopharmaceutical theranostics pair are 177Lu/68Ga, 111In, 223Ra/99Tc, 18NaF, 131I/123I, 124I, etc.
Radiopharmaceutical theranostics is gaining traction and will most likely be able to expand its scope to include new cancer biomarkers and indications in future. Hence, rise in the prevalence of cancer is projected to propel the demand for radiopharmaceutical theranostics over the next few years.
Request for Analysis of COVID19 Impact on Radiopharmaceutical Theranostics Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82604
Lutetium (Lu) 177 to Dominate Global Market
In terms of radioisotope, the global radiopharmaceutical theranostics market has been classified into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market in 2020 and the trend is anticipated to continue during the forecast period. The favorable nuclear characteristics as well as easy availability of high activity levels of high specific activity 177Lu are the major factors for the widespread interest in the clinical use of this radionuclide.
Oncology to Offer Lucrative Opportunities
Based on application, the global radiopharmaceutical theranostics market has been categorized into oncology, cardiology, and others. The oncology segment dominated the global radiopharmaceutical theranostics market in 2020. Most of the radioisotopes are used in oncology for diagnosis or radiation therapy. 68 Ga DOTATE and 177 Lu DOTATOC is the commonly used theranostics pair in diagnosis and treatment of neuroendocrine tumors.
High Number of Cyclotrons Facilities to Drive Global Market
In terms of source, the global radiopharmaceutical theranostics market has been bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment dominated the market in 2020. The segment is expected to expand at the highest CAGR from 2021 to 2031. The segment is likely to witness rapid growth, owing to a large number of existing cyclotron facilities across the world.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=82604
Targeted Therapeutic (Rx) to be Promising Segment
Based on approach, the global radiopharmaceutical theranostics market has been classified into targeted therapeutic (Rx) and companion diagnostic (DX). The targeted therapeutic (Rx) segment dominated the market in 2020. The segment is projected to expand at the highest CAGR from 2021 to 2031. Increasing evidence supports the efficacy and safety of targeted therapeutics, as well as an increase in overall survival.
Hospitals to be Major End Users
In terms of end user, the global radiopharmaceutical theranostics market has been divided into academic & research institutes, hospitals, and others. The hospitals segment dominated the market in 2020. The segment is anticipated to expand at the highest CAGR from 2021 to 2031. Rise in number of hospital facilities and favorable outcomes of treatment in hospitals due to the availability of a range of treatment options lead to high preference to hospitals.
North America to Lead Radiopharmaceutical Theranostics Market
The global radiopharmaceutical theranostics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2020, followed by Europe. North America accounted for a major share of the global radiopharmaceutical theranostics market in 2020. The high prevalence of neuroendocrine tumors (NETs) drives the radiopharmaceutical theranostics market in North America. Over 12,000 people in the U.S. are diagnosed with neuroendocrine tumors each year. The sensitivity and specificity of Ga-68 and Lu-177 as a theranostics pair have been evaluated in a number of clinical trials. This factor is expected to fuel the growth of the market in the region.
Buy now Radiopharmaceutical Theranostics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=82604<ype=S
Competition Landscape
The global radiopharmaceutical theranostics market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, GE Healthcare, Theragnostics Ltd, NuView Life Sciences, Jubilant Pharma Limited, Lantheus Holdings, Inc., Curium Pharma, Bayer AG, and Clarity Pharmaceuticals. New product development through robust R&D activities and mergers & acquisitions are the key strategies adopted by these players to expand business in the global radiopharmaceutical theranostics market.
More Trending Reports by Transparency Market Research:
https://www.prnewswire.co.uk/news-releases/continuous-r-amp-d-to-expand-therapeutic-use-of-platelet-rich-plasma-prp-in-regenerative-therapies-offer-profitable-opportunities-to-platelet-rich-plasma-market-players-global-market-valuation-to-reach-us-811-34-mn-by-2030-tmr-study-825481498.html
https://www.prnewswire.com/news-releases/increase-in-demand-for-new-therapies-for-effective-management-to-drive-global-menopausal-hot-flashes-treatment-market-says-tmr-301378552.html
https://www.prnewswire.com/news-releases/plant-based-vaccines-market-is-expected-to-reach-us-2-34-billion-by-2031-end-emergence-of-numerous-infectious-diseases-to-fuel-growth-of-the-market-says-tmr-301385503.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
0 notes
Last Seen Blogs
fatexposedloser
Property
2lovely
2lovely
amagnificentobsession
A Magnificent Obsession
greasergirls
loud & trashy!
zabidisameon
Untitled